1Goldheber SZ,Visani L,De-Rosa M.Acate pulmonary embolism:Clinical outcomes in the International Cooperative pulmonary Embobism Registry (ICOPER)[J].Lancet,1999,353:1386-1389.
3[1]Dalen JE.Resolution rate of acute pulmonary embolism in man.N Engl J Med,1969,280:1194
4[2]Jerjes - SC,Raminrez - RA,Garcia Ml,et al.Streptokinase and heparin versus heparin alone in massive pulmonary embolism;a randomized controlled trial.J Thromb Thrombolysis,1995,2:227 -9
5[3]Goldhaber SZ,Kessler GM,Heit J,et al.Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.Lancet,1988,2:293 - 298
6[4]Goldhaber SZ.Recombinant tissue - type plasminogen activater versus a novel dosing controlled multicenter trial.J Am Coll Cardiol,1992,20( 1 ) :24 - 30
7[5]Goldhober SZ,Aggnelli G,Levine MN.Reduced dose alteplase vs conventional alteplase infution for pulmonary embolism thrombolysis an international multicenter randomized trial.Chest,1994,106:718-724
8[6]Goldhaber SZ,Haire WD,Feldstein ML.Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right - ven-tricular function and pulmonary perfusion.Lancet,1993,341:507 -511
9[7]Jezek V.Thrombolysis in acute pulmonary embolism: to whom,how much and how? Eur Heart J,1997,18:1045
10[8]Konstantinides S,Geibet A,olschewski M ,et al.Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry.Circulation,1997,96:882 - 8
